Evidence map›Paper›PMID 39159285›Full record

ReviewNeuro-oncology2024

Enhancing neuro-oncology care through equity-driven applications of artificial intelligence.

Mulki Mehari, Youssef Sibih, Abraham Dada, Susan M Chang, Patrick Y Wen, Annette M Molinaro, Ugonma N Chukwueke, Joshua A Budhu, Sadhana Jackson, J Ricardo McFaline-Figueroa and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Health disparities in neurology.Nature reviews. Neurology · 2025
    Review
  5. Value of artificial intelligence in neuro-oncology.The Lancet. Digital health · 2025
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mulki MehariDepartment of Neurosurgery, University of California, San Francisco, San Francisco, California, USA.
Youssef SibihDepartment of Neurosurgery, University of California, San Francisco, San Francisco, California, USA.
Abraham DadaDepartment of Neurosurgery, University of California, San Francisco, San Francisco, California, USA.
Susan M ChangDivision of Neuro-Oncology, University of California San Francisco and Weill Institute for Neurosciences, San Francisco, California, USA.
Patrick Y WenCenter for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Annette M MolinaroDepartment of Neurosurgery, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-9854-7404
Ugonma N ChukwuekeCenter for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Joshua A BudhuDepartment of Neurology, Memorial Sloan Kettering Cancer Center, Department of Neurology, Weill Cornell Medicine, Joan & Sanford I. Weill Medical College of Cornell University, New York, New York, USA.ORCID 0000-0002-8923-9784
Sadhana JacksonSurgical Neurology Branch, National Institute of Neurological Disorders and Stroke, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0001-6700-5621
J Ricardo McFaline-FigueroaCenter for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Alyx PorterDivision of Neuro-Oncology, Department of Neurology, Mayo Clinic, Phoenix, Arizona, USA.ORCID 0000-0003-0666-1320
Shawn L Hervey-JumperDepartment of Neurosurgery, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0003-4699-260X

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Intratumoral functional connectivity with implications on synaptogenesis and aphasia recovery in adult astrocytic WHO II-III gliomaK08NS110919 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HERVEY-JUMPER, SHAWN L. · 2019 to 2023
$1.0M
NCI NIH HHS P30 CA008748NIH HHSNINDS NIH HHS K08 NS110919
6 · The paper itself

Abstract

The disease course and clinical outcome for brain tumor patients depend not only on the molecular and histological features of the tumor but also on the patient's demographics and social determinants of health. While current investigations in neuro-oncology have broadly utilized artificial intelligence (AI) to enrich tumor diagnosis and more accurately predict treatment response, postoperative complications, and survival, equity-driven applications of AI have been limited. However, AI applications to advance health equity in the broader medical field have the potential to serve as practical blueprints to address known disparities in neuro-oncologic care. In this consensus review, we will describe current applications of AI in neuro-oncology, postulate viable AI solutions for the most pressing inequities in neuro-oncology based on broader literature, propose a framework for the effective integration of equity into AI-based neuro-oncology research, and close with the limitations of AI.

Indexed as

Artificial IntelligenceBrain NeoplasmsMedical OncologyHealthcare DisparitiesHealth EquityHumansartificial intelligencehealth disparitieshealth equitymachine learningneuro-oncology

Identifiers

PMID39159285
PMCPMC11534320

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.